Pfizer and Innovent's GLP-1 Drugs Clear China Insurance Hurdle

The news marks a positive development as Pfizer's GLP-1 drug receives insurance coverage in China, potentially unlocking significant sales potential for the company in the Chinese market. Technically, the RSI stands at 48.6, indicating a neutral zone, while the MACD is above its signal line, signaling a short-term bullish move. Although the SMA20 being below the SMA50 suggests medium-term weakness, the news could drive an upward movement in the short term. However, yesterday's 2.3% decline and overall market conditions pose a risk of limited upside.

GOOGL shares closed 2.9% lower in the last session, with the RSI approaching oversold territory at 33.4. The MACD remains below the signal line in negative territory, indicating weak short-term momentum. The price is trading below both the 20-day (343.27) and 50-day (351.35) moving averages. Although the news headline does not directly impact GOOGL, the overall market sentiment weakness and deteriorating technical indicators could sustain downward pressure in the near term. However, the RSI nearing oversold levels may signal a potential buying opportunity for a rebound.